BioSpace News Archive

BioSpace’s Recruitment Market Q3 Update shows that both employers and employees in the life sciences have noticed quiet quitting in action. Read on to find out the signs, effects and prevalence of it in biopharma.

ViewRay, Inc. announced that the final primary endpoint results from the phase III randomized single-center MIRAGE trial were presented at the 64th Annual Meeting of the American Society for Radiation Oncology being held October 23-26, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Immunic, Inc. announced that the company will release its financial results for the third quarter ended September 30, 2022, including a corporate update, on Thursday, November 3, 2022, before the opening of the U.S. financial markets.

Biotech’s illustrious Industry Excellence Awards were announced at the AusBiotech 2022 national conference in Perth – recognising outstanding contribution and achievement.

BIOLASE, Inc. announced that it will release third quarter 2022 financial and operating results on Thursday, November 10, 2022 after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

23andMe Holding Co. reported that the U.S. Food and Drug Administration granted 510 clearance for its pharmacogenetics report for SLCO1B1 to include interpretive drug information for simvastatin, a common drug used to treat high cholesterol and triglyceride levels.

NextGen Healthcare, Inc. announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

BioXcel Therapeutics, Inc. announced that it will release its third quarter 2022 financial results on Thursday, November 10, 2022 before the open of the U.S. financial markets.

Foghorn® Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, announced the election of Thomas Lynch Jr., M.D., to its Board of Directors.

Vaccitech plc announced the publication of research in preclinical animal models demonstrating the potential of Vaccitech’s SNAPvax for use in a novel paradigm for cancer treatment referred to as “VAX-INNATE.”